Short answer: The labels differ, and the decision belongs with the oncology team. Older vaginal estrogen labels, such as Vagifem and Estrace cream, list breast cancer or a history of it as a reason not to use them. The Estring label revised in April 2026 instead says to talk with a provider if you have or had an estrogen-dependent cancer. Large observational studies of survivors found no higher breast cancer death rate with vaginal estrogen.
| Label | Wording on breast cancer |
|---|---|
| Vagifem (estradiol inserts) | Contraindicated in breast cancer or a history of breast cancer |
| Imvexxy (estradiol inserts) | Contraindicated in breast cancer or a history of breast cancer |
| Estrace cream (estradiol 0.01%) | Should not be used with known, suspected, or history of cancer of the breast |
| Estring (estradiol ring), revised 4/2026 | Contraindicated in known or suspected estrogen-dependent neoplasia; patient leaflet says to talk with your provider if you have or had an estrogen-dependent cancer |
The Vagifem and Estring labels both say some estradiol from the vagina reaches the bloodstream. The Estring label reports that the amount absorbed is about 8% of what the ring releases each day, and that blood estradiol levels stayed within the range of untreated women.
In November 2025, FDA asked makers of menopausal hormone therapy to remove the breast cancer, heart disease and dementia language from the boxed warning. For local vaginal estrogen products, FDA asked that safety information be condensed to focus on what matters for a product used in the vagina. FDA said the changes followed questions about whether the boxed warnings were warranted, particularly for local vaginal estrogen.
Labels are updated one product at a time, which is why Estring already reads differently from labels last revised in 2023 or 2024. See hormone therapy and mammograms for more on how the systemic labels describe breast risk.
Both studies are observational: women chose or were prescribed vaginal estrogen rather than being assigned at random, so other differences between users and non-users may affect the results. The Danish aromatase inhibitor finding is one reason oncologists may look at the type of breast cancer treatment when this comes up.
Whether vaginal estrogen fits after breast cancer depends on the cancer type, the current treatment (such as tamoxifen or an aromatase inhibitor), and the symptoms. Useful things to bring are the symptom history and the list of current medicines. Dose Track can log a vaginal estrogen dose alongside other medicines so the full list is easy to show.
Read more on Dose Track: Estring vs Vagifem · Vagifem side effects · Vaginal estradiol · Vulvar and vaginal atrophy · Aromatase inhibitor